Literature DB >> 25616766

[Reduced morbidity in resection of residual tumors after chemotherapy for seminoma].

D Pfister1, D Porres2, V Matveev2, A Heidenreich2.   

Abstract

BACKGROUND: Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) is associated with complications and decreased adjunctive surgery. Little data are available concerning PC-RPLND in patients with advanced seminomas and residual retroperitoneal tumor lesions. We examined intra- and postoperative complications as well as the frequency of adjunctive surgeries in patients with seminoma and compared the data to a cohort of patients with non-seminomatous germ cell tumors (NSGCT) who underwent PC-RPLND. PATIENTS AND METHODS: In our retrospective analysis, 580 patients (43 patients with advanced seminomas and 537 patients with NSGCT) underwent PC-RPLND between 1989 and 2010. The surgical approach was preferred via midline incision or a thoracoabdominal approach depending on the location of the residual tumor.
RESULTS: Of the 43 patients with seminoma, a total number of 13 adjunctive surgeries were performed in 7 patients. There were only three intraoperative complications, two postoperative complications (prolonged intestinal paralyses). There were no significant differences in adjunctive surgeries and postoperative complications (p=0.49 and p=0.133) between the two groups. There were significantly fewer intraoperative complications in favor of seminomas (p=0.001).
CONCLUSION: PCRLND in seminomas and NSGCT is a demanding surgical intervention. In contrast to other series we did not find significant differences in the two patient groups concerning adjunctive surgeries and postoperative complications. The indication for PCLND in patients with seminoma is limited, but if necessary it can be performed safely in experienced centers.

Entities:  

Keywords:  Germ cell neoplasms; Laparotomy; Lymph node excision; Neoplasm metastasis; Testicular cancer

Mesh:

Substances:

Year:  2015        PMID: 25616766     DOI: 10.1007/s00120-014-3708-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  20 in total

1.  Management of post-chemotherapy residual masses in advanced seminoma.

Authors:  Aude Flechon; Emmanuelle Bompas; Pierre Biron; Jean-Pierre Droz
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

2.  [Value of radiotherapy of residual tumors after chemotherapy of metastatic seminomas].

Authors:  M Bamberg; J Classen
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

3.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.

Authors:  Cédric Vallier; Pierre-Henri Savoie; Jean-Robert Delpero; Franck Bladou; Gwenaëlle Gravis; Naji Salem; Dominique Rossi; Jochen Walz
Journal:  World J Urol       Date:  2014-01-20       Impact factor: 4.226

4.  International patterns and trends in testis cancer incidence.

Authors:  Mark P Purdue; Susan S Devesa; Alice J Sigurdson; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2005-07-10       Impact factor: 7.396

Review 5.  Surgery for a post-chemotherapy residual mass in seminoma.

Authors:  H W Herr; J Sheinfeld; H S Puc; R Heelan; D F Bajorin; P Mencel; G J Bosl; R J Motzer
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

6.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?

Authors:  Ashraf A Mosharafa; Richard S Foster; Bradley C Leibovich; Richard Bihrle; Cynthia Johnson; John P Donohue
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

7.  Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy.

Authors:  M J Peckham; W F Hendry
Journal:  Br J Urol       Date:  1985-12

Review 8.  Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.

Authors:  D F Bajorin; H Herr; R J Motzer; G J Bosl
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

9.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz-Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

10.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

View more
  1 in total

Review 1.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.